www.allsides.com
FDA approves Eli Lilly Alzheimer’s drug, expanding treatment options in the U.S.
The Food and Drug Administration on Tuesday approved Eli Lilly’s Alzheimer’s drug donanemab, expanding the limited treatment options for the mind-wasting disease in the U.S.
The agency approved the treatment, which will be sold under the brand name Kisunla, for adults with early symptomatic Alzheimer’s disease, according to the company.
Nearly 7 million Americans have the condition, the fifth-leading cause of death for adults over 65, according to the Alzheimer’s...
New Posts (Home)
ChatBox
Popular Posts 
Game Zone
Top PodCasts
